Inbrija (levodopa) — Highmark
Intermittent treatment of OFF episodes in patients with Parkinson’s disease treated with carbidopa/levodopa
Initial criteria
- age ≥ 18 years
- Diagnosis of Parkinson’s disease (ICD-10: G20)
- Experiencing OFF episodes despite an optimally dosed oral carbidopa/levodopa regimen
- Experiencing at least 2 hours per day of OFF time per day
Reauthorization criteria
- Prescriber attests that the member has experienced positive clinical response to therapy
Approval duration
12 months